Staphylococcus aureus endocarditis: Identifying prognostic factors using a method derived from morbidity and mortality conferences

Benjamin Lefèvre, Antoine Legoff, Mathilde Boutrou, François Goehringer, Willy Ngueyon-Sime, Catherine Chirouze, Matthieu Revest, Véronique Vernet Garnier, Xavier Duval, François Delahaye, Vincent Le Moing, Christine Selton-Suty, Laura Filippetti, Bruno Hoen, Nelly Agrinier, Benjamin Lefèvre, Antoine Legoff, Mathilde Boutrou, François Goehringer, Willy Ngueyon-Sime, Catherine Chirouze, Matthieu Revest, Véronique Vernet Garnier, Xavier Duval, François Delahaye, Vincent Le Moing, Christine Selton-Suty, Laura Filippetti, Bruno Hoen, Nelly Agrinier

Abstract

Objectives: Lethality of Staphylococcus aureus (Sa) infective endocarditis (IE) is high and might be due to yet unidentified prognostic factors. The aim of this study was to search for new potential prognostic factors and assess their prognostic value in SaIE.

Materials and methods: We used a two-step exploratory approach. First, using a qualitative approach derived from mortality and morbidity conferences, we conducted a review of the medical records of 30 patients with SaIE (15 deceased and 15 survivors), randomly extracted from an IE cohort database (NCT03295045), to detect new factors of possible prognostic interest. Second, we collected quantitative data for these factors in the entire set of SaIE patients and used multivariate Cox models to estimate their prognostic value.

Results: A total of 134 patients with modified Duke definite SaIE were included, 64 of whom died during follow-up. Of the 56 candidate prognostic factors identified at the first step, 3 had a significant prognostic value in multivariate analysis: the prior use of non-steroidal anti-inflammatory drugs [aHR 3.60, 95% CI (1.59-8.15), p = 0.002]; the non-performance of valve surgery when indicated [aHR 1.85, 95% CI (1.01-3.39), p = 0.046]; and the decrease of vegetation size on antibiotic treatment [aHR 0.34, 95% CI (0.12-0.97), p = 0.044].

Conclusion: We identified three potential SaIE prognostic factors. These results, if externally validated, might eventually help improve the management of patients with SaIE.

Keywords: Staphylococcus aureus; infective endocarditis; morbidity and mortality conference method; prognostic factors; survival.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Lefèvre, Legoff, Boutrou, Goehringer, Ngueyon-Sime, Chirouze, Revest, Vernet Garnier, Duval, Delahaye, Le Moing, Selton-Suty, Filippetti, Hoen and Agrinier.

Figures

FIGURE 1
FIGURE 1
Flow chart of patients with Staphylococcus aureus infective endocarditis (SaIE) selected from EI2008. IE, infective endocarditis, Sa, Staphylococcus aureus.

References

    1. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. (2019) 40:3222–32. 10.1093/eurheartj/ehz620
    1. Olmos C, Vilacosta I, Fernández-Pérez C, Bernal JL, Ferrera C, García-Arribas D, et al. The evolving nature of infective endocarditis in Spain. J Am Coll Cardiol. (2017) 70:2795–804. 10.1016/j.jacc.2017.10.005
    1. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. (2012) 54:1230–9. 10.1093/cid/cis199
    1. Fowler VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. (2005) 293:3012. 10.1001/jama.293.24.3012
    1. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the international collaboration on endocarditis merged database. Clin Infect Dis. (2005) 41:507–14. 10.1086/431979
    1. Nadji G, Rémadi JP, Coviaux F, Mirode AA, Brahim A, Enriquez-Sarano M, et al. Comparison of clinical and morphological characteristics of Staphylococcus aureus endocarditis with endocarditis caused by other pathogens. Heart Br Card Soc. (2005) 91:932–7. 10.1136/hrt.2004.042648
    1. Abdallah L, Habib G, Remadi J-P, Salaun E, Casalta J-P, Tribouilloy C. Comparison of prognoses of Staphylococcus aureus left-sided prosthetic endocarditis and prosthetic endocarditis caused by other pathogens. Arch Cardiovasc Dis. (2016) 109:542–9. 10.1016/j.acvd.2016.02.010
    1. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med. (2009) 169:463–73. 10.1001/archinternmed.2008.603
    1. Leroy O, Georges H, Devos P, Bitton S, De Sa N, Dedrie C, et al. Infective endocarditis requiring ICU admission: epidemiology and prognosis. Ann Intensive Care. (2015) 5:45. 10.1186/s13613-015-0091-7
    1. Muñoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodríguez-Abella H, et al. Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study. Medicine. (2015) 94:e1816. 10.1097/MD.0000000000001816
    1. Olmos C, Vilacosta I, Fernandez C, Lopez J, Sarria C, Ferrera C, et al. Contemporary epidemiology and prognosis of septic shock in infective endocarditis. Eur Heart J. (2013) 34:1999–2006. 10.1093/eurheartj/ehs336
    1. Tagliari AP, Steckert GV, Silveira LMV, Kochi AN, Wender OCB. Infective endocarditis profile, prognostic factors and in-hospital mortality: 6-year trends from a tertiary university center in South America. J Card Surg. (2020) 35:1905–11. 10.1111/jocs.14787
    1. Nunes MCP, Guimarães-Júnior MH, Murta Pinto PHO, Coelho RMP, Souza Barros TL, Faleiro Maia N, et al. Outcomes of infective endocarditis in the current era: early predictors of a poor prognosis. Int J Infect Dis. (2018) 68:102–7. 10.1016/j.ijid.2018.01.016
    1. DiNubile MJ, Calderwood SB, Steinhaus DM, Karchmer AW. Cardiac conduction abnormalities complicating native valve active infective endocarditis. Am J Cardiol. (1986) 58:1213–7. 10.1016/0002-9149(86)90384-X
    1. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European society of cardiology (ESC)endorsed by: European association for cardio-thoracic surgery (EACTS), the European association of nuclear medicine (EANM). Eur Heart J. (2015) 36:3075–128. 10.1093/eurheartj/ehv319
    1. Chirouze C, Alla F, Fowler VG, Sexton DJ, Corey GR, Chu VH, et al. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the international collaboration of endocarditis–prospective cohort study. Clin Infect Dis. (2015) 60:741–9. 10.1093/cid/ciu871
    1. Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods M-C, Peetermans WE. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J. (2006) 28:196–203. 10.1093/eurheartj/ehl427
    1. Chu VH, Cabell CH, Benjamin DK, Kuniholm EF, Fowler VG, Engemann J, et al. Early predictors of in-hospital death in infective endocarditis. Circulation. (2004) 109:1745–9. 10.1161/01.CIR.0000124719.61827.7F
    1. Gregor A, Taylor D. Morbidity and mortality conference: its purpose reclaimed and grounded in theory. Teach Learn Med. (2016) 28:439–47. 10.1080/10401334.2016.1189335
    1. Haute autorité de Santé H France. Revue de Mortalité et de Morbidité (RMM) Outil D’amélioration Des Pratiques Professionnelles. (2015). Available online at: (accessed August 21, 2020).
    1. Orlander JD, Barber TW, Fincke BG. The morbidity and mortality conference: the delicate nature of learning from error. Acad Med. (2002) 77:1001–6. 10.1097/00001888-200210000-00011
    1. Hill AB. The environment and disease: association or causation? J R Soc Med. (2015) 108:32–7. 10.1177/0141076814562718
    1. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Anti Inflamm Anti Allergy Agents Med Chem. (2012) 11:52–64. 10.2174/187152312803476255
    1. Le Turnier P, Boutoille D, Joyau C, Veyrac G, Asseray N. Bacterial infections and NSAIDs exposure? Seek septic complications. Eur J Intern Med. (2017) 41:e33–4. 10.1016/j.ejim.2017.03.004
    1. Basille D, Plouvier N, Trouve C, Duhaut P, Andrejak C, Jounieaux V. Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia: a cohort study. Lung. (2017) 195:201–8. 10.1007/s00408-016-9973-1
    1. Leroy S, Marc E, Bavoux F, Tréluyer J-M, Gendrel D, Bréart G, et al. Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study. Clin Drug Investig. (2010) 30:179–85. 10.2165/11532890-000000000-00000
    1. Fernández Guerrero ML, González López JJ, Goyenechea A, Fraile J, de Górgolas M. Endocarditis caused by Staphylococcus aureus: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. Medicine. (2009) 88:1–22. 10.1097/MD.0b013e318194da65
    1. Hill EE, Herregods M-C, Vanderschueren S, Claus P, Peetermans WE, Herijgers P. Management of prosthetic valve infective endocarditis. Am J Cardiol. (2008) 101:1174–8. 10.1016/j.amjcard.2007.12.015
    1. Rohmann S, Erbel R, Darius H, Görge G, Makowski T, Zotz R, et al. Prediction of rapid versus prolonged healing of infective endocarditis by monitoring vegetation size. J Am Soc Echocardiogr. (1991) 4:465–74. 10.1016/S0894-7317(14)80380-5
    1. Scheggi V, Alterini B, Olivotto I, Del Pace S, Zoppetti N, Tomberli B, et al. Embolic risk stratification and prognostic impact of early surgery in left-sided infective endocarditis. Eur J Intern Med. (2020) 78:82–7. 10.1016/j.ejim.2020.04.017
    1. Mohananey D, Mohadjer A, Pettersson G, Navia J, Gordon S, Shrestha N, et al. Association of vegetation size with embolic risk in patients with infective endocarditis: a systematic review and meta-analysis. JAMA Intern Med. (2018) 178:502. 10.1001/jamainternmed.2017.8653
    1. Maraolo AE, Giaccone A, Gentile I, Saracino A, Bavaro DF. Daptomycin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infection with or without endocarditis: a systematic review and meta-analysis. Antibiotics. (2021) 10:1014. 10.3390/antibiotics10081014
    1. Lee S, Song K-H, Jung S-I, Park WB, Lee SH, Kim Y-S, et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea. Clin Microbiol Infect. (2018) 24:152–8. 10.1016/j.cmi.2017.07.001
    1. Shi C, Xiao Y, Zhang Q, Li Q, Wang F, Wu J, et al. Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis. BMC Infect Dis. (2018) 18:508. 10.1186/s12879-018-3418-9
    1. Rindone JP, Mellen CK. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia: meta-analysis: cefazolin vs. antistaphylococcal penicillin. Br J Clin Pharmacol. (2018) 84:1258–66. 10.1111/bcp.13554
    1. Eljaaly K, Alshehri S, Erstad BL. Systematic review and meta-analysis of the safety of antistaphylococcal penicillins compared to cefazolin. Antimicrob Agents Chemother. (2018) 62:e1816–7. 10.1128/AAC.01816-17
    1. Bidell MR, Patel N, O’Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. (2018) 73:2643–51. 10.1093/jac/dky259
    1. Samura M, Kitahiro Y, Tashiro S, Moriyama H, Hamamura Y, Takahata I, et al. Efficacy and safety of daptomycin versus vancomycin for bacteremia caused by methicillin-resistant Staphylococcus aureus with vancomycin minimum inhibitory concentration > 1 μg/mL: a systematic review and meta-analysis. Pharmaceutics. (2022) 14:714. 10.3390/pharmaceutics14040714
    1. Lecomte R, Bourreau A, Deschanvres C, Issa N, Le Turnier P, Gaborit B, et al. Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis of a prospective multicentre French cohort study. Clin Microbiol Infect. (2020) 27:1015–21. 10.1016/j.cmi.2020.08.044
    1. Lefèvre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C, et al. Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study. Eur J Clin Microbiol Infect Dis. (2021) 40:2605–16. 10.1007/s10096-021-04313-3

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa